A clinical trial testing a modified approach to bowel cancer treatment has produced extraordinary results, with zero patients experiencing cancer recurrence nearly three years after treatment. The findings challenge conventional treatment protocols and offer new hope for patients facing one of the most common cancer diagnoses.
The NEOPRISM-CRC clinical trial, led by researchers from University College London and UCL Hospital, altered both the timing and type of medication administered to bowel cancer patients. Rather than following the standard protocol of surgery followed by chemotherapy, patients received the immunotherapy drug pembrolizumab before their surgical procedures.
The results, scheduled for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 in April, demonstrate a stark contrast to traditional outcomes. Initial findings showed that 59 percent of patients had no signs of disease after treatment with pembrolizumab and their operation. The 33-month follow-up data reveals that none of these patients have experienced a return of their cancer.
Dr. Kai-Keen Shiu, Chief Investigator of the trial from UCL Cancer Institute and a Consultant Medical Oncologist at UCLH, emphasized the significance of these findings. "Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging and strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers," he stated.
The trial results become even more impressive when compared against standard treatment expectations. Approximately 25 percent of patients who undergo conventional surgery and post-operative chemotherapy typically experience relapse after three years. The study suggests that immunotherapy administered before surgery may provide more durable, long-lasting cancer control for high-risk bowel cancer cases.
Researchers have developed additional tools to enhance treatment precision. The team analyzed blood samples to understand the treatment's effectiveness and created personalized blood tests capable of detecting whether therapy has succeeded and whether cancer remains present in the bloodstream. These diagnostic advances could revolutionize how physicians determine appropriate treatment intensity for individual patients.
"What is particularly exciting is that we now may be able to predict who will respond to the treatment using personalized blood tests and immune profiling," Dr. Shiu added. "These tools could help us tailor our approach, identifying patients who are doing well and may need less therapy before and after surgery versus patients at higher risk of disease progression or relapse who need additional treatment."
The disease burden remains substantial across multiple countries. Bowel cancer ranks as the fourth most common cancer in the United Kingdom, with approximately 44,000 cases diagnosed annually. In the United States, where the disease is referred to as colorectal cancer, it represents the third most common cancer diagnosis and the second leading cause of cancer-related death for both men and women. For adults under 50, colorectal cancer has become the number one cause of cancer-related mortality.
Early detection remains critical for positive outcomes. Nine in ten patients treated for stage 1 bowel cancer survive for five years or more. However, certain tumor subtypes respond less favorably to treatment and demonstrate higher recurrence rates. Five-year survival drops to 65 percent in stage 3 and 10 percent in stage 4 bowel cancer, underscoring the importance of improved treatment protocols.
Yanrong Jiang, first author of the latest abstract and clinical PhD student at the UCL Cancer Institute, described the research team's approach to monitoring patient outcomes. "As a research team, we were thrilled to be able to follow patients very closely using the personalized blood tests," Jiang stated. "When tumor DNA disappeared from the blood, patients were much more likely to have no cancer remaining, and this matched the long-term results we're now seeing."
Jiang also noted that immune profiling from tumor tissue, conducted before patients begin their first treatment cycle, can help predict response. The research team hopes these tests may guide treatment decisions in a more practical and timely manner.
Patient experiences reflect the trial's success. Christopher Burston, 73 years old, reported returning to normal activities three years after his treatment while maintaining regular follow-up appointments. "The recovery went fine. I didn't have any problems. And since then, I've been feeling pretty much back to normal. I feel very lucky that I've reached the stage where my main problem is age rather than cancer or any illness," he said.
The trial's success builds upon earlier results demonstrating that the drug led to major tumor shrinkage in patients with stage 2 or 3 bowel cancer. The combination of improved survival rates, personalized diagnostic tools, and reduced treatment burden represents a significant advancement in cancer care that could reshape treatment protocols for thousands of patients facing this diagnosis.